Vitro Diagnostics Inc. (fka VODG)

[JonesBur]

Noticed news came out this morning. It would be nice to know who they sell their discovery tools to and at the very least, how much is being sold or maybe even an announcement of an order. So doesn't mean a whole lot overall but it is nice to see something from them about once a month.


GOLDEN, CO / ACCESSWIRE / May 3, 2016 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within tumor tissue and serve various functions including suppression of immune responses to cancerous cells, support of tumor cell growth and enhancement of metastasis. Modern immunotherapy has evolved into CAR-T technology (chimeric antigen receptor T cells) whereby patient's immune cells are genetically engineered to migrate to, attach to and eliminate cancer cells. Several biotech firms are developing CAR-T cancer immunotherapeutic products including Juno Therapeutics, Kite Pharma and Ziopharm Oncology. Some early trials for treatment of leukemia show nearly complete remission using this therapy. However, CAFs present within solid tumors continue to block engineered T cells and require intervention to maximize immunotherapy to completely eradicate cancerous cells (PNAS 110: 20212, 2013).

Our CAF product line now includes several tumor-specific CAFs including lung, colorectal, pancreatic and we also provide our specialized cell culture medium, Vitro Plus III™, for the expansion and use of these cell lines in cell-based assays for cancer drug discovery. With the addition of breast CAFs we now provide a broader array of CAF offerings to advance the race for a cure for cancer. Immunotherapy is at the forefront of the fright to eliminate cancer through a targeted approach designed to selectively eradicate cancer tumor cells from the body: http://www.cancer.gov/about-cancer/treatment/research/car-t-cells.

Dr. Jim Musick, President & CEO of Vitro Biopharma said, "We are very pleased to announce the latest addition to our cancer research tools. Use of the immune system to selectively target and eliminate cancerous cells from the body was pioneered by Dr. Steven Rosenberg at the National Cancer Institute (NCI). The recent expansion to CAR-T technology adds enhanced specificity and potency to the process. Immunotherapy has the potential to provide significant advances to our abilities to treat cancer and may be a crucial tool in the eradication of cancer. Vitro Biopharma has a history of involvement in cancer research through a previous contract with NCI in the 1990's to supply a recombinant human tumor marker, CEA (carcinoembryonic antigen). More recently, our pancreatic primary fibroblast cell line and CAFs have been used extensively in cancer research. We now sell our cancer drug discovery tools to large biopharmaceutical companies and several other research labs throughout the world. We also plan to further expand our CAF product line in the future."